Enigma and Applera sign real-time PCR licenses

These agreements provide Enigma with access under patents owned or controlled by Applera for real-time PCR thermal cyclers and real-time PCR methods and compositions in specific fields.

The real-time instrument patent license agreement covers Enigma’s current and pipeline instrument platforms of fully automated, real-time thermal cyclers across the commercial market sectors of research and applied markets. This agreement also provides Enigma with an option for a license in clinical diagnostics. The application kit license agreement covers a portfolio of important patents covering reverse transcription-based methods, real-time PCR detection process and 5′ nuclease assays and compositions, for use in fields excluding human diagnostics.